Dasher Neuroscience Completes Patient Enrollment for Phase 2 Trial
Dasher Neuroscience Holdings Inc. has completed patient recruitment for its global Phase 2 clinical trial evaluating its lead AI-derived drug candidate, YA-101, for multiple system atrophy (MSA).
Dasher Neuroscience Holdings Inc. has announced the completion of patient enrollment for its global Phase 2 clinical trial. The study is investigating the efficacy of the company's lead artificial intelligence-derived drug candidate, YA-101, for the treatment of multiple system atrophy (MSA).
The trial, initiated in 2026, has now reached its full recruitment capacity. This Phase 2 study is expected to provide key data on the safety and potential effectiveness of YA-101 in patients diagnosed with MSA. MSA is a rare and progressive neurodegenerative disorder for which there is currently no cure.
Dasher Neuroscience's approach utilizes AI to expedite and optimize the drug discovery and development process. The company aims to identify and advance novel therapies for conditions with significant unmet medical needs.
The upcoming results from the Phase 2 trial will inform Dasher Neuroscience's decisions regarding the further development of YA-101, including potential progression to later-stage clinical studies. This milestone represents a significant step in the company's efforts to address challenging neurological diseases.